Watch someone with Parkinson's disease try to track a finger moving across their field of vision, and you may notice the eyes undershoot the target, then correct, then undershoot again. That small stutter has a name, saccadic hypometria, and on October 7, 2026, Arvinas reported that an experimental drug changed it in a dose dependent way over 28 days. The company, based in New Haven, Connecticut, presented the finding as a late breaking oral presentation and e-poster at the International Congress of Parkinson's Disease and Movement Disorders in Seoul, South Korea.
The drug, called ARV-102, is built to clear a protein called LRRK2 from brain tissue. LRRK2 has drawn attention in Parkinson's research for years because mutated versions of its gene are among the most common known genetic contributors to the disease. In this single-center, randomized, double-blind, placebo-controlled trial, 24 people with Parkinson's disease took ARV-102 by mouth at 20, 40, or 80 milligrams daily, or took a placebo, for 28 days. Using a digital eye-tracking system, researchers found that the more LRRK2 fell in spinal fluid, the bigger the change in that eye movement measure. Spinal fluid testing also showed drops in proteins linked to inflammation and cellular waste clearance, CD68 and GPNMB, and rises in proteins linked to nerve-cell connections, NPTX2 and CBLN4. The amount of LRRK2 cleared tracked with the change in CD68 as well.
Ilaria Conti, the company's vice president of clinical research, said in the release that "this study was not designed to assess clinical efficacy," while describing the biomarker and eye-movement links as encouraging. That caution matters, because a separate clinical meeting report on the same data noted that scores on the standard Parkinson's disease motor scale numerically favored the drug over placebo, but with confidence intervals wide enough to leave real uncertainty. The same report found no relationship between how much LRRK2 a patient started with and how much it fell during treatment, a detail that complicates any simple story about dose and response.
None of this tells a family whether a drug like this changes the course of Parkinson's disease. It tells researchers that a biological target can be hit, and that hitting it moves something measurable in the eyes and in spinal fluid. That is the work that has to happen before a bigger question can even be asked.